Thomas Jefferson University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University System of Maryland

Icahn School of Medicine at Mount Sinai

Christoph Wirblich

Matthias Johannes Schnell

Lisa E Hensley

Drishya Kurup

Reed F Johnson

Christopher M Coleman

Gene Tan

Matthew B Frieman

Matthew S Frieman

Christine Rettew Fisher

The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.

Multivalent vaccines for rabies virus and coronaviruses

The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

Coronavirus disease (COVID-19) vaccine

The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.

Compositions and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies

Growing community of inventors

Philadelphia, PA, United States of America

Christoph Wirblich